TribLIVE

| Business

 
Larger text Larger text Smaller text Smaller text | Order Photo Reprints

Merck, Pfizer sue to block proposed version of AzaSite

Email Newsletters

Click here to sign up for one of our email newsletters.

On the Grid

From the shale fields to the cooling towers, Trib Total Media covers the energy industry in Western Pennsylvania and beyond. For the latest news and views on gas, coal, electricity and more, check out On the Grid today.

MRK $47.80 -$0.15

PFE $29.16 +$0.07

MYL $31.54 -$0.14

at close on MONDAY

By Bloomberg News
Tuesday, June 18, 2013, 12:01 a.m.
 

Merck & Co. and Pfizer Inc. sued generic drugmaker Mylan Pharmaceuticals Inc. to block it from selling a copy of AzaSite, an antibiotic eye solution for fighting bacterial conjunctivitis.

Mylan told Pfizer, Merck and InSite Vision Inc. on May 1 that it sought Food and Drug Administration approval to sell a generic version of AzaSite, according to a lawsuit filed on Friday in federal court in Trenton, N.J. The complaint asks a judge to prevent Mylan from entering the market before the patents expire. One ends in 2018, and the other three expire in 2019, according to the FDA website.

Subscribe today! Click here for our subscription offers.

 

 


Show commenting policy

Most-Read Business Headlines

  1. Operating loss mounts at Highmark’s core hospital system
  2. FNB buying Harrisburg-based Metro Bancorp
  3. Polymer Enterprises finds success in specialty tire market
  4. Obama’s Clean Power plan doesn’t change much; opponents remain firm
  5. Coal producer Alpha Natural Resources files for bankruptcy
  6. Shell shovels millions into proposed Beaver County plant site
  7. Slump in energy stocks drags down Dow, S&P
  8. Oil prices slip on persistent fears of glut
  9. Auto sales strong in July on SUV, luxury demand
  10. Labor Department ruling broadens definition of ‘employee’
  11. Muni bond funds stressed